Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.77 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.99 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | MMP1 | P03956 | 1/20 | 0.99 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.99 |
| ▸ | ACHE | P22303 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL4450369 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL663859 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL16447653 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL29363805 | 1.00 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL359364 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL572716 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL30822976 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL29359605 | 0.99 | PAX8 (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL12313065 | 0.99 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA | |
| Irinotecan SCHEMBL131381 | 0.99 | GLA (1.00) | GLAGAAKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22091 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| EP-4748449-A2 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-12622906-B2 | Treatment and prognosis of pancreatic cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-05-12 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4720132-A1 | COMBINATION THERAPIES INVOLVING CLAUDIN 18.2 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12589157-B1 | Compositions of drug delivery agents and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260078184-A1 | LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-19 | — | — | US | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1080726-A1 | AGENTS FOR RELIEVING SIDE EFFECTS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2001-03-07 | — | — | EP | claimed |
| US-6159935-A | TREATMENT OF DIARRHEA WITH IRINOTECAN OR SALTS | PHARMACIA & UPJOHN CO. (IT) | 2000-12-12 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| CN-1261790-A | Self-emulsifying formulation for lipophilic compounds | PHARMACIA & UPJOHN CO LLC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-1003516-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | The George Washington University (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0999826-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999065493-A9 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | UNIV GEORGE WASHINGTON (US) | 2000-03-23 | — | — | WO | claimed |
| WO-1999065493-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-12-23 | — | — | WO | claimed |
| WO-1999006024-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-11 | — | — | WO | claimed |